Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib

Fig. 2

The efficacy of Osimertinib based on tissue or plasma T790M mutation. A Comparison of PFS between patients with tissue/pleural effusion T790M mutation and those with plasma T790M mutation. B Comparison of ORR and DCR between patients with tissue/pleural effusion T790M mutation and those with plasma T790M mutation. C Correlation analysis of plasma T790M AF and PFS. D Comparison of plasma T790M AF among three groups according to the BOR to Osimertinib

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us